Abstract
The regional pharmacokinetics as well as the pharmacodynamics of pilocarpine-loaded nanoparticles for the treatment of glaucoma were investigated and compared to a solution of this drug. Poiybutylcy-anoacrylate nanoparticles were prepared by an emulsion polymerization process. Formulations with different drug concentrations (2–6%) as well as different particle concentrations were investigated and analyzed for size and drug loading. Drug binding to the particles was achieved at a level of 10–18% of the total drug content. The colloidal nanoparticles were sufficiently small (diameter: 100–300 nm) for a non-irritating application to the eye. All preparations were applied to the eyes of New Zealand white rabbits which were treated with betamethasone before to create an elevated intraocular pressure (IOP). Pilocarpine concentrations, assayed from aqueous humor using gaschromatography, increased by 23% (AUC) for nanoparticle suspensions compared to aqueous reference solutions. Additionally, t1/2 was prolonged and the elimination coefficient was significantly decreased. Pharmacodynamic effects such as miosis and IOP reduction were investigated. tmax values of aqueous humor concentration were observed to be in a similar time range as miosis tmax readings. It was found that at lower drug contents a more pronounced prolongation of miosis was achieved with nanoparticles versus a standard solution. The lOP-reduction was significantly prolonged with nanoparticles preparations; whereas maximum reduction was obtained with a reference solution after 1–2 hours, it was reached with nanoparticles at about 2–3 hours. Differences between nanoparticles and aqueous solutions were most pronounced at lower drug concentrations.
Similar content being viewed by others
REFERENCES
M. Diestelhorst. Charakteristik und Diagnostik wichtiger Glaukomformen, Pharm. Ztg. 136(10):9–13 (1991).
G. Keren and G. Treiser. Effect of aceclidine (+) isomer and pilocarpine on the intraocular pressure decrease and the miosis in glaucomatous eyes. Effect on accommodation in normal eyes of young subjects, Ophthalmologica 180:181–187 (1980).
R. Weekers, Y. Delamrcelle, and J. Gustin. Treatment of ocular hypertension by adrenalin and diverse sympathomimetic amines. Am. J. Ophthalmol. 40:666–672 (1956).
S. S. Chrai and J. R. Robinson. Corneal permeation of topical pilocarpine nitrate in the rabbit. Am. J. Ophthalmol. 77:735–739 (1974).
T. F. Patton and J. R. Robinson. Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes. J. Pharm. Sci. 65:1295–1301 (1976).
R. Gurny, T. Boye T, and H. Ibrahim. Ocular therapy with nanoparticulate systems for controlled drug delivery. J. Controlled Rel. 2:353–361 (1985).
T. Harmia, P. Speiser, and J. Kreuter. A solid colloidal drug delivery system for the eye: encapsulation of pilocarpine in nanoparticles. J. Microencapsul. 3:3–12 (1986).
R. W. Diepold. Entwicklung und Untersuchung von kolloidalen Depot-Arzneistoffträgersystemen zur Glaukombehandlung. Dissertation, Fachbereich Biochemie, Pharmazie und Lebens-mittelchemie, JWG-Universität, Frankfurt, a.M., 1988.
R. W. Diepold, J. Kreuter, J. Himber, R. Gurny, V. H. L. Lee, J. R. Robinson, M. F. Saettone, and O. E. Schnaudigel. Comparison of different models for the testing of pilocarpine eyedrops using conventional eyedrops and a novel depot formulation (nanoparticles). Graefe's Arch. Clin. Exp. Ophthalmol. 227:188–193 (1989).
L. Bonomi, S. Perfetti, E. Noya, R. Bellucci, and L. Tomazzoli. Experimental corticosteroid ocular hypertension in the rabbit. Graefe's Arch. Clin. Exp. Ophthalmol. 209:73–82 (1978).
J. Kreuter. Evaluation of nanoparticles as drug-delivery systems I: Preparation methods. Pharm. Acta Helv. 58:196–208 (1983).
M. C. Makoid and J. R. Robinson. Pharmacokinetics of topically applied pilocarpine in the albino rabbit eye. J. Pharm. Sci. 68:435–442 (1979).
J. Meier. Pharmakokinetische Grundlagen. In H. Sucker (ed.), Pharmazeutische Technologie, Georg Thieme, Stuttgart, 1978, pp. 275–276.
D. Leu. Polyacrylic nanoparticles as controlled release drug delivery systems, Dissertation Nr. 7184, ETH-Zürich, 1983.
J. Kreuter. Nanoparticles and nanocapsules — new dosage forms in the nanometer size range. Pharm. Acta Helv. 53:33–39 (1978).
R. W. Wood and J. R. Robinson. Ocular disposition of pilocarpine in the pigmented rabbit: site of metabolism. Int. J. Pharm. 29:127–135 (1986).
S. Lerman and B. Reininger. Simulated sustained release pilocarpine therapy and aqueous humor dynamics. Canad. J. Ophthal. 6:14–23 (1971).
B. Schwartz. Physiological effects of the corticosteroids on the eye. In B. Schwartz (ed.) Corticosteroids and the eye. Little Brown, Boston, 1966, pp. 753–765.
S. Yoshida and S. Mishima. A pharmacokinetic analysis of the pupil response to topical pilocarpine and tropicamide. Jpn. J. Ophthalmol. 19:121–138 (1975).
D. M. Maurice and S. Mishima. Ocular Pharmacokinetics. In M. L. Sears (ed.), Handbook of Experimental Pharmacology — Pharmacology of the Eye, Springer, Berlin, Heidelberg, New York, 1984, 69:pp. 19–116.
A. Zimmer, J. Kreuter and J. R. Robinson. Studies on the transport pathway of PBCA-nanoparticles in ocular tissues. J. Microencapsul. 8:497–504 (1991).
I. Ahmed and T. F. Patton. Disposition of timolol and inulin in rabbit eye following corneal versus non-corneal absorption. Int. J. Pharm. 38:9–21 (1987).
S. Mishima. Clinical pharmacokinetics of the eye. Invest. Ophthalmol. Vis. Sci. 21:504–541 (1981).
S. Miller, K. Himmelstein, and T. F. Patton. A physiologically based pharmacokinetic model for the intraocular distribution of pilocarpine in rabbits. J. Pharm. Biopharm. 9:653–677 (1981).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zimmer, A., Mutschler, E., Lambrecht, G. et al. Pharmacokinetic and Pharmacodynamic Aspects of an Ophthalmic Pilocarpine Nanoparticle-Delivery-System. Pharm Res 11, 1435–1442 (1994). https://doi.org/10.1023/A:1018995923348
Issue Date:
DOI: https://doi.org/10.1023/A:1018995923348